Iovance Biotherapeutics Up Over 23%, On Pace For Largest Percent Increase Since November 2025 -- Data Talk

Dow Jones
Feb 24

Iovance Biotherapeutics Inc (IOVA) is currently at $3.56, up $0.67 or 23.01%

 

--Would be highest close since July 23, 2025, when it closed at $3.97

--On pace for largest percent increase since Nov. 6, 2025, when it rose 27.62%

--Currently up seven consecutive days; up 41.07% over this period

--Longest winning streak since June 14, 2021, when it rose for seven straight trading days

--Best seven day stretch since the seven days ending July 24, 2025, when it rose 69.59%

--Up 39.41% month-to-date; on pace for best month since July 2025, when it rose 49.42%

--Up 30.22% year-to-date

--Down 97.76% from its all-time closing high of $159.00 on June 7, 2011

--Down 33.43% from 52 weeks ago (Feb. 25, 2025), when it closed at $5.34

--Down 33.55% from its 52-week closing high of $5.35 on Feb. 26, 2025

--Up 114.16% from its 52-week closing low of $1.66 on May 16, 2025

--Traded as high as $3.86; highest intraday level since July 24, 2025, when it hit $4.04

--Up 33.56% at today's intraday high; largest intraday percent increase since Nov. 6, 2025, when it rose as much as 38.67%

 

All data as of 10:26:10 AM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

February 24, 2026 10:28 ET (15:28 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10